Generation Bio Co. (NASDAQ:GBIO – Get Free Report) has earned an average rating of “Hold” from the six research firms that are currently covering the firm, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $8.00.
GBIO has been the subject of several recent analyst reports. Needham & Company LLC reissued a “buy” rating and issued a $10.00 price target on shares of Generation Bio in a research note on Wednesday, April 10th. Wedbush reissued an “outperform” rating and issued a $5.00 price target on shares of Generation Bio in a research note on Thursday, March 7th.
Get Our Latest Analysis on Generation Bio
Institutional Inflows and Outflows
Generation Bio Price Performance
Shares of GBIO opened at $2.83 on Friday. The company has a market cap of $188.17 million, a P/E ratio of -1.44 and a beta of 2.78. The stock has a fifty day moving average price of $3.16 and a 200 day moving average price of $2.19. Generation Bio has a 12 month low of $0.86 and a 12 month high of $6.98.
Generation Bio (NASDAQ:GBIO – Get Free Report) last issued its quarterly earnings data on Wednesday, March 6th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.12). The company had revenue of $2.88 million during the quarter, compared to analysts’ expectations of $3.05 million. As a group, research analysts anticipate that Generation Bio will post -1.34 earnings per share for the current year.
About Generation Bio
Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.
Read More
- Five stocks we like better than Generation Bio
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- How to Calculate Options Profits
- Hilton Demonstrates Asset Light is Right for Investors
- Using the MarketBeat Dividend Tax Calculator
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Generation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generation Bio and related companies with MarketBeat.com's FREE daily email newsletter.